2,432 reports of this reaction
5.6% of all ORLISTAT reports
#2 most reported adverse reaction
RECTAL DISCHARGE is the #2 most commonly reported adverse reaction for ORLISTAT, manufactured by Haleon US Holdings LLC. There are 2,432 FDA adverse event reports linking ORLISTAT to RECTAL DISCHARGE. This represents approximately 5.6% of all 43,367 adverse event reports for this drug.
Patients taking ORLISTAT who experience rectal discharge should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RECTAL DISCHARGE is moderately reported among ORLISTAT users, representing a notable but not dominant share of adverse events.
In addition to rectal discharge, the following adverse reactions have been reported for ORLISTAT:
RECTAL DISCHARGE has been reported as an adverse event in 2,432 FDA reports for ORLISTAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
RECTAL DISCHARGE accounts for approximately 5.6% of all adverse event reports for ORLISTAT, making it one of the most commonly reported side effect.
If you experience rectal discharge while taking ORLISTAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.